Dr. David Fajgenbaum

And we talked about earlier.

18% of people and 20% and 25.

And these things don't work in everyone.

But if they work in you and they could work in you, I really want to make sure that we try it in you because the work's been done to prove that it can help some people.

Yeah, so as we shared earlier, the sort of way that our AI platform works is we look across every drug and every disease and basically see what matches score the highest.

And so we start from there.

So we don't pick a disease a priori and say we're going to work on it.

We let the algorithm point us towards a match.

And then our team looks into it, and we spend lots of time reviewing through them.

Our team has now reviewed over 6,000 of the top matches.

It's out of 75 million.

So we've got a ways to go.

But 6,000 brilliant MDs, PhDs reviewing through them, looking for treatments that are hiding in plain sight.

And out of the ones we've looked through, we currently have

six active programs.

We're actually just getting ready to add three more.

So we'll have nine active programs in the next month or so that look across conditions that I mentioned earlier.

The example of breast cancer is one of them.

That's one of the more common cancers.

We've got another program in a condition called Bachman-Bopp syndrome, where it's only been described in a